Kafkas University Faculty of Medicine, Department of Emergency Medicine, Kars, Turkey.
Pamukkale University Faculty of Medicine, Department of Emergency Medicine, Denizli, Turkey.
Am J Emerg Med. 2021 Feb;40:77-82. doi: 10.1016/j.ajem.2020.12.010. Epub 2020 Dec 10.
This study aimed to compare the therapeutic efficacy of dimenhydrinate and metoclopramide in patients with nausea and vertigo.
A prospective, double-blind, randomized clinical trial was performed on patients who presented to the emergency department (ED) with nausea and vertigo in the six month period between Nov 1st 2012 and May 1st 2013. Adult patients who were 18 to 65 years old presenting to the ED with nausea and vertigo or motion sickness were included in the study. A total of 200 patients were divided into 2 groups who were admitted to ED with complaints of vertigo accompanied by nausea. In the first group, 50 mg dimenhydrinate and 10 mg metoclopramide infusions were given intravenously for 15 min. The efficacy of treatment was measured by using a 10 mm Visual Analog Scale (VAS) performed at 0, 15 and the 30th minute. The primary outcome variable was a reduction in vertigo intensity documented on the VAS at the 30th minute after medication administration.
A total of 200 patients were included in the randomization (n=100 in both groups). The baseline vertigo VAS scores were 7.57±1.42 in the dimenhydrinate (DMT) group and 7.27±1.40 in the metoclopramide (MTP) group (p=0.09). In the 30th minute of treatment, the average vertigo VAS score was 2.46 ± 2.39 in the DMT group and 2.31±1.96 in the MTP group; no significant differences were detected between groups. The baseline nausea VAS scores were 7.62±1.48 in the DMT group and 7.45±1.27 in the MTP group (p=0.36). In the 30th minute of treatment the average vertigo VAS score decreased to 2.27±2.24 in the DMT group and 2.70±2.48 in the MTP group, no significant differences were detected between groups. No significant differences were detected between nausea VAS changes and vertigo VAS changes at 30th minutes of the treatment (p=0.06, p=0.85 respectively). Rescue medication need was similar in both treatment groups (p=0.94). No significant differences were detected about the side effects which are sedation (p=0.56) and hypotension (p=0.57).
In conclusion, this prospective, double-blind, randomized study showed that both DMT and MTP have similar efficacy in reducing nausea and vertigo symptoms in the ED.
本研究旨在比较晕海宁和甲氧氯普胺治疗恶心和眩晕患者的疗效。
2012 年 11 月 1 日至 2013 年 5 月 1 日期间,对因恶心和眩晕到急诊科就诊的患者进行了前瞻性、双盲、随机临床试验。本研究纳入年龄在 18 至 65 岁之间、因恶心和眩晕或晕车到急诊科就诊的成年患者。将 200 例患者分为两组,每组 100 例,均因眩晕伴恶心入院。在第一组中,静脉注射 50mg 晕海宁和 10mg 甲氧氯普胺,持续 15 分钟。治疗效果通过在给药后 0、15 和 30 分钟时使用 10mm 视觉模拟量表(VAS)进行评估。主要结局变量为用药后 30 分钟时 VAS 记录的眩晕强度降低。
共有 200 例患者纳入随机分组(每组 100 例)。晕海宁(DMT)组和甲氧氯普胺(MTP)组基线眩晕 VAS 评分分别为 7.57±1.42 和 7.27±1.40(p=0.09)。治疗 30 分钟时,DMT 组平均眩晕 VAS 评分为 2.46 ± 2.39,MTP 组为 2.31±1.96;两组间无显著差异。DMT 组和 MTP 组基线恶心 VAS 评分分别为 7.62±1.48 和 7.45±1.27(p=0.36)。治疗 30 分钟时,DMT 组恶心 VAS 评分平均下降至 2.27±2.24,MTP 组下降至 2.70±2.48,两组间无显著差异。治疗 30 分钟时,眩晕 VAS 评分变化与恶心 VAS 评分变化之间无显著差异(p=0.06,p=0.85)。两组的急救药物需求相似(p=0.94)。两组的副作用,包括镇静(p=0.56)和低血压(p=0.57),均无显著差异。
总之,这项前瞻性、双盲、随机研究表明,在急诊科,晕海宁和甲氧氯普胺在减轻恶心和眩晕症状方面具有相似的疗效。